Novavax Inc vs Sempra Energy — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Sempra Energy trades at $84.9 (market cap $55.89B). The key difference: Sempra Energy is far larger — about 33.3× Novavax Inc's market cap, and Sempra Energy pays a 3.08% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SRE | |
|---|---|---|
Market Cap | $1.68B | $55.89B |
Sector | Health | Utilities |
52-Week High | $11.19 | $99.75 |
52-Week Low | $6.22 | $81.70 |
Enterprise Value | $1.26B | $92.52B |
Dividend Yield | — | 3.08% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Sempra is an energy infrastructure company with regulated utility and energy network businesses. Its operations include electric and gas utilities as well as energy infrastructure in North America.
Read more on SRE →